Real-world treatment outcomes for pancreatic neuroendocrine tumours: a single tertiary referral institute experience.

ESMO Gastrointest Oncol · 2026 · PMC13080929 · PMID 41994027

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the 20 patients who received systemic therapy, everolimus showed a trend towards improved PFS compared with chemotherapy (5-year PFS: 46.9% versus 16.7%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.